TGA seeks input on MDMA, psilocybin downschedule

The TGA has decided to seek further advice in relation to psilocybin and MDMA and their therapeutic use The TGA says this will include “an independent expert review into the therapeutic value, risks and benefits to public health outcomes for these substances as well as seeking additional advice from the Advisory Committee on Medicines Scheduling